Ann: Chimeric to present at ********* Hidden Gems webinar, page-6

You heard it right, like IMU they only announce patient 1 dosed. The next update is on safety, dose escalation, early efficacy signals ....

Finally an easy overview how undervalued CHM is right now.

She included slides highlighting the current M&A activities in the CAR-T market:

5/6 CD19 CAR-Ts approved and applied but currently 260 ( several variations ) more in development. M&A in full swing in the CAR-T space but only assets with an approach that either completes Big Pharma pipeline or will be newly added will be considered in M&A. CHM assets definitely meet BPs M&A criteria.

While the CD19 space is over crowed, the CD17 and CLTX just got the first competitors emerging - Why? Because the CHM's data show they work / will work ( CD 17) in humans. CHM in both areas most advanced world wide.